Log In Sign up
The largest database of trusted experimental protocols

Nod cg prkdcscid il2rgtm1sug jictac

Manufactured by Taconic Biosciences
Visit Supplier
Sourced in United States

NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac is a type of immunodeficient mouse model developed by Taconic Biosciences. It is a genetically modified mouse strain that lacks functional T cells, B cells, and natural killer cells, making it a useful tool for research involving engraftment of human cells and tissues.

Automatically generated - may contain errors

Lab products found in correlation

Matrigel, by Corning (2 mentions) Anti mouse cd45 apc cy7 antibodies, by BioLegend (2 mentions) Rpmi 1640, by Thermo Fisher Scientific (1 mentions) Penicillin streptomycin, by Thermo Fisher Scientific (1 mentions) Crtac ncr foxn1nu, by Taconic Biosciences (1 mentions) Cann cg foxn1nu crl, by Charles River Laboratories (1 mentions) Nod mrkbomtac prkdc scid, by Taconic Biosciences (1 mentions) C b igh 1b icrtac prkdcscid, by Taconic Biosciences (1 mentions) Nod cg prkdcscid il2rgtm1wjl szj mice, by Jackson ImmunoResearch (1 mentions) Nod cg prkdc, by Jackson ImmunoResearch (1 mentions) Nod mice, by Jackson ImmunoResearch (1 mentions) Ciea nog immunodeficient mice, by Taconic Biosciences (1 mentions)

18 protocols using nod cg prkdcscid il2rgtm1sug jictac

1

NOG Mouse Bladder Organoid Implantation

Check if the same lab product or an alternative is used in the 5 most similar protocols
All experiments using animals were performed according to protocols approved by the Institutional Animal Care and Use Committee (IACUC) at Columbia University Medical Center. 6–8 week old male NOG (NOD.Cg-PrkdcscidIl2rgtm1Sug/JicTac; Taconic) mice were used for ultrasound-guided delivery of organoids diluted in 50% Matrigel/media into the mouse bladder wall. Mice were observed for clinical signs of disease daily, and mice were euthanized according to IACUC-approved criteria.
Lee S.H., Hu W., Matulay J.T., Silva M.V., Owczarek T.B., Kim K., Chua C.W., Barlow L.J., Kandoth C., Williams A.B., Bergren S.K., Pietzak E.J., Anderson C.B., Benson M.C., Coleman J.A., Taylor B.S., Abate-Shen C., McKiernan J.M., Al-Ahmadie H., Solit D.B, & Shen M.M. (2018). Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell, 173(2), 515-528.e17.
+ Open protocol
+ Expand
2

Adoptive T-cell Transfer in Melanoma Xenograft Model

Check if the same lab product or an alternative is used in the 5 most similar protocols
Immune deficient NOG mice (NOD.Cg-PrkdcScidIL2rgtm1sug/JicTac, Taconic) were housed in individually ventilated cages at University of Copenhagen, and supplied only autoclaved or sterilized water, food pellets and nesting material. The study was approved by local ethics committee.
NOG mice were inoculated with 2.5 × 106 cells of the human melanoma cell line, FM82 (ESTDAB-27), subcutaneous (sc.) on the left flank. Tumor growth was measured with calipers twice a week, and represented as tumor surface (mm2). For studies of tumor homing, animals were treated with tail vein administration of 15 × 106 MAGE-A3 specific Mock or CXCR2 transduced T cells when tumor size reached approx. 30 mm2. ACT was combined with intra peritoneal (ip.) injection of 6 × 105 IU rh-IL2 at the day of ACT and twice daily for the subsequent two days. For study of tumor homing, blood was collected from the mandibular vein immediately prior to culling by cervical dislocation 7 days after ACT. Tumor, spleen, lungs and bone marrow were resected and kept in RPMI 1640 + 1% penicillin/streptomycin (Gibco) on ice until processing.
Idorn M., Skadborg S.K., Kellermann L., Halldórsdóttir H.R., Holmen Olofsson G., Met Ö, & thor Straten P. (2018). Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model. Oncoimmunology, 7(8), e1450715.
+ Open protocol
+ Expand
3

Establishment of Colorectal Tumor PDX Models

Check if the same lab product or an alternative is used in the 5 most similar protocols
Tumor and matched normal specimens were obtained from patients undergoing liver metastasectomies or colon resections of primary disease at the University of Michigan University Hospital (Ann Arbor, MI). All patients provided informed written consent and samples were procured with approval of the University of Michigan Institutional Review Board (HUM00065489). Specimens were obtained within four hours of surgery and immediately transferred to DMEM/F12 media supplemented with 10% fetal bovine serum and 1% Penicillin-Streptomycin-Glutamine at 4°C. A portion of normal colon specimens were fixed in 10% neutral buffered formalin (NBF) and the remainder snap frozen in liquid nitrogen. Portions of tumor specimens were either fixed in 10% NBF, snap frozen in liquid nitrogen, or divided into fragments approximately 3 × 3 mm for subcutaneous implantation into female 6–7 week old CIEA NOG mice (NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac from Taconic) using an 11G Trocar needle. Tumor-implanted mice were monitored for tumor growth for up to four months following implantation. Xenografted tumors from the NOG mice were passaged into female 6–7 week old NCR nude mice (CrTac:NCr-Foxn1nu from Taconic) for model expansion. PDX models were maintained in nude mice for no more than four passages before fresh material from the freezer was used to regenerate the line.
Ziemke E.K., Dosch J.S., Maust J.D., Shettigar A., Sen A., Welling T.H., Hardiman K.M, & Sebolt-Leopold J.S. (2015). Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy that Co-Targets MEK and CDK4/6. Clinical cancer research : an official journal of the American Association for Cancer Research, 22(2), 405-414.
+ Open protocol
+ Expand
4

Establishing Patient-Derived Xenograft Models

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Surgical samples and blood were collected with informed consent under an Institutional Review Board-Approved Protocol. Following collection, the first 13 PDXs were established by implanting tumor fragments to the flank of nude mice as previously described (13 (link)). The latter models were established using a similar surgical procedure but involved placing the fragment on the bilateral 4th mammary fat pads of female nude mice (Department of Radiation Oncology-MD Anderson Cancer Center) or NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac (Taconic). Estrogen supplementation was provided to one of the specimens BCX.066 as it was 60% ER+ during presurgery clinical pathological analysis. All animal experiments were approved by Institutional Animal Care and Use Committee.
Evans K.W., Yuca E., Akcakanat A., Scott S.M., Arango N.P., Zheng X., Chen K., Tapia C., Tarco E., Eterovic A.K., Black D.M., Litton J.K., Yap T.A., Tripathy D., Mills G.B, & Meric-Bernstam F. (2017). A Population of Heterogeneous Breast Cancer Patient Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild Type Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 23(21), 6468-6477.
+ Open protocol
+ Expand
5

Xenograft Transplantation of Human HSPCs

Check if the same lab product or an alternative is used in the 5 most similar protocols
Six- to 8-wk-old female CIEA NOG mice (NOD.Cg PrkdcscidIl2rgtm1Sug/JicTac) were purchased from Taconic Biosciences. One day after electroporation, 1 × 105 cells were administered by tail-vein injection after sublethal X-ray irradiation (75 cGy). Before transplantation, flow cytometry confirmed that >98% of HSPCs were CD34+. Mice were randomly assigned to each experimental group and evaluated in a blinded fashion.
Jensen T.I., Mikkelsen N.S., Gao Z., Foßelteder J., Pabst G., Axelgaard E., Laustsen A., König S., Reinisch A, & Bak R.O. (2021). Targeted regulation of transcription in primary cells using CRISPRa and CRISPRi. Genome Research, 31(11), 2120-2130.
+ Open protocol
+ Expand
6

Xenograft Tumor Growth Measurement

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mouse experiments were approved by the Landesamt für Gesundheit und Soziales Berlin (Reg 0010/19) and complied with the German Animal Welfare Act. B cell lines frozen 60 days after transduction were thawed and cultured for 2 weeks. 100 μl containing 5 million cells in 50% MatriGel (Corning, Cat. No. 356234) were injected subcutaneously into female, 2-month-old NOG mice (NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac; Taconic Biosciences). Three times per week the tumor volume was measured and calculated using the formula 0.5 a × b2, where a and b are the long and short diameters of the tumor, respectively. After reaching a tumor volume of ≥ 1.5 cm3 animals had to be sacrificed (humane endpoint).
Zhang J., Sommermann T., Li X., Gieselmann L., de la Rosa K., Stecklum M., Klein F., Kocks C, & Rajewsky K. (2023). LMP1 and EBNA2 constitute a minimal set of EBV genes for transformation of human B cells. Frontiers in Immunology, 14, 1331730.
+ Open protocol
+ Expand
7

Xenograft Model of Leukemia

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
All animal experiments were performed with the approval of Dana-Farber Cancer Institute's Institutional Animal Care and Use Committee. NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac (NOG) mice were obtained from Taconic Biosciences. Nonirradiated 8- to 12-week-old adult mice were transplanted with previously established PDXs (25 (link)) via tail-vein injection (250,000 cells/mouse). Engraftment of human cells (hCD45+) was analyzed and monitored longitudinally by weekly bleeding to quantify hCD45+ cells in the peripheral blood by flow cytometry with human CD45-PE and anti-mouse CD45-APC-Cy7 antibodies (BioLegend). Mice were monitored closely to detect disease onset, and treatment started when hCD45+ cells were detectable in the peripheral blood. Mice were randomly assigned to either normal or 0.1% VTP-50469 rodent special diet (25 (link)). Mice were bled weekly to monitor leukemia burden as described above and euthanized when showing clinical signs of disease (experimental endpoint). Leukemia cells from a subset of these animals were harvested after 7 days of treatment to perform RNA-seq.
Soto-Feliciano Y.M., Sánchez-Rivera F.J., Perner F., Barrows D.W., Kastenhuber E.R., Ho Y.J., Carroll T., Xiong Y., Anand D., Soshnev A.A., Gates L., Beytagh M.C., Cheon D., Gu S., Liu X.S., Krivtsov A.V., Meneses M., de Stanchina E., Stone R.M., Armstrong S.A., Lowe S.W, & Allis C.D. (2022). A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin–MLL Inhibition. Cancer Discovery, 13(1), 146-169.
+ Open protocol
+ Expand
8

Xenograft Mouse Model Development

Check if the same lab product or an alternative is used in the 5 most similar protocols
Six-week-old immunodeficient male mice (BALB/c nude, n=58, CAnN.Cg-Foxn1nu/Crl, Charles River, Germany; NOG mice, n=7, NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac Taconic, Denmark; NOD.SCID mice, n=6, NOD/MrkBomTac-Prkdc SCID, Taconic, Denmark; or SHrN hairless NOD.SCID, n=13, NOD.Cg-PrkdcscidHrhr/NCrHsd, Envigo, France, Table 7) were maintained under controlled pathogen-free conditions (20–21 °C, 30–60% relative humidity, 12-hour light cycle, soya-free chow, and autoclaved drinking water).
Tissue specimens were aseptically cut into 1–2 mm3 pieces in a laminar hood using razor blades. Tumor pieces were implanted subcutaneously into the inter-scapular fat pads of immunodeficient mice. A total of 33 mice were supplemented with 20–25 mg Te propionate pellets, which were pressed in-house from Te-propionate powder (Sigma-Aldrich). Nineteen mice were supplemented with 12.5 mg 5α-DHT pellets (Innovative Research of America, FL, USA). Thirty-two mice received no hormone pellets.
At sacrifice, gross necropsy was performed, and the findings were documented. Tumors were removed and collected for histology or transplanted further to second or third generation of mice using the same protocol as described above.
Valta M., Ylä-Pelto J., Lan Y., Kähkönen T., Taimen P., Boström P.J., Ettala O., Khan S., Paulin N., Elo L.L., Koskinen P.J., Härkönen P, & Tuomela J. (2020). Critical evaluation of the subcutaneous engraftments of hormone naïve primary prostate cancer. Translational Andrology and Urology, 9(3), 1120-1134.
+ Open protocol
+ Expand
9

Xenograft Model of B-ALL in NOG Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
NOG mice (NOD.Cg-PrkdcscidIl2rgtm1Sug/JicTac) were purchased from Taconic. All animal experiments were approved by Verona University Ethical Committee (http://www.medicina.univr.it/fol/main?ent=bibliocr&id=85) and authorized by Ministerial Decree (16/2014-B). B-ALL animal experiments were in accordance with the Amsterdam Protocol on animal protection and welfare and conducted according to the guidelines of Federation of European Laboratory Animal Science Associations (FELASA).
Sandri S., De Sanctis F., Lamolinara A., Boschi F., Poffe O., Trovato R., Fiore A., Sartori S., Sbarbati A., Bondanza A., Cesaro S., Krampera M., Scupoli M.T., Nishimura M.I., Iezzi M., Sartoris S., Bronte V, & Ugel S. (2017). Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy. Oncotarget, 8(50), 86987-87001.
+ Open protocol
+ Expand
10

Murine Models for Xenograft Studies

Check if the same lab product or an alternative is used in the 5 most similar protocols
C57BL/6 and C57BL/-Tg (HLA-A2.1) 1 Enge/J (6–8 week-old male), and NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ mice (6–8 week-old male), known as NOD scid gamma (NSG), were purchased from Jackson Laboratory. Functionally equivalent NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac (6–8 week-old male), known as NOG, and C.B-Igh-1b/IcrTac-Prkdcscid (6–8 week-old male), known as CB17 SCID, were purchased from Taconic. All studies were conducted in accordance with IACUC approved protocols.
Veomett N., Dao T., Liu H., Xiang J., Pankov D., Dubrovsky L., Whitten J.A., Park S.M., Korontsvit T., Zakhaleva V., Casey E., Curcio M., Kharas M.G., O’Reilly R.J., Liu C, & Scheinberg D.A. (2014). Therapeutic Efficacy of an Fc-Enhanced TCR-Like Antibody to the Intracellular WT1 Oncoprotein. Clinical cancer research : an official journal of the American Association for Cancer Research, 20(15), 4036-4046.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!